Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / NOTE 3.000%10/1
-
Market price (% of par)
-
100.3%
-
Total 13F principal
-
$161,123,000
-
Principal change
-
-$997,500
-
Total reported market value
-
$161,965,451
-
Number of holders
-
17
-
Value change
-
-$1,201,655
-
Number of buys
-
9
-
Number of sells
-
6
Institutional Holders of KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 as of Q2 2021
As of 30 Jun 2021,
KARYOPHARM THERAPEUTICS INC - NOTE 3.000%10/1 was held by
17 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$161,123,000
in principal (par value) of the bond.
The largest 10 bondholders included
CITADEL ADVISORS LLC, Davidson Kempner Capital Management LP, LAZARD ASSET MANAGEMENT LLC, Opti Capital Management, LP, STEELHEAD PARTNERS LLC, Farallon Capital Management LLC, CNH PARTNERS LLC, CAPSTONE INVESTMENT ADVISORS, LLC, BANK OF MONTREAL /CAN/, and CREDIT SUISSE AG/.
This page lists
17
institutional bondholders reporting positions
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.